TELUS Health diabetes step therapy program
Information for pharmacy providers

Program structure
TELUS Health launched the diabetes step therapy program on October 5, 2017.

<table>
<thead>
<tr>
<th>Step</th>
<th>Therapeutic class</th>
</tr>
</thead>
<tbody>
<tr>
<td>Step 1</td>
<td>Biguanides (immediate release – Metformin)</td>
</tr>
</tbody>
</table>
| Step 2 | Biguanides (extended release – Metformin ER)  
Sulfonylureas (e.g. Glyburide)  
SGLT-2 inhibitors (Empagliflozin +/- Metformin and Canagliflozin +/- Metformin)  
GLP-1 Agonists (Liraglutide) |
| Step 3* | Meglitinides (e.g. Repaglinide)  
Thiazolidinedione (e.g. Pioglitazone)  
GLP-1 Agonists (e.g. Semaglutide)  
SGLT-2 inhibitors (e.g. Dapagliflozin)  
DPP-4 inhibitors (e.g. Sitagliptin)  
Alpha-glucosidase inhibitors (e.g. Acarbose)  
GLP-1 agonist & insulin combo (e.g. Insulin glargine/lirinestide) |

*Any products that don’t meet criteria for step 1 or 2 are added to step 3 automatically.

How does the program work at the pharmacy?

1. Plan member presents prescription for processing at the pharmacy.
2. TELUS Health adjudication engine verifies whether or not a step therapy program applies to the particular claim.
3. If a prior step has not been fulfilled, you might see one of the following return messages:
   a. ‘Preference or Step Drug Available’
   b. ‘Prerequisite DIN required first’

Please note: the information in this document pertains to the diabetes step therapy program maintained by TELUS Health only. For information regarding any other step therapy programs, plan members will need to contact their insurance carriers.

Program details

• The program consists of 3 steps which were established based on evidence of clinical safety, efficacy and cost
  - The program includes oral and non-insulin injectable diabetic medications
  - The program can be customized to require that single or multiple requirements are met before progressing to drugs or devices in the next step of the program
    o i.e. trial of 2 or more drugs in a therapy class before progressing to the next step
• Guidelines published by Diabetes Canada and the Canadian Agency for Drugs and Technologies in Health (CADTH) were used during the build of each step within the program